II. Indications
- See Glycopeptide Antibiotic
- Complicated Skin Infections (including MRSA)
- Hospital acquired or Ventilator associated Staphylococcus AureusPneumonia
- Not considered a first-line agent (other agents are preferred)
III. Contraindications
- eGFR <50 ml/min
- Mortality increased in Hospital Acquired Pneumonia (including Ventilator associated) compared with Vancomycin
- Known QT Prolongation (e.g. congenital, Drug-Induced QTc Prolongation)
- Decompensated Heart Failure
- Severe Left Ventricular Hypertrophy
- Unfractionated Heparin use (caution with Warfarin use)
IV. Mechanism
V. Dosing
- IV formulation must be infused within 4 hours when left at room Temperature
- Standard Dosing (eGFR>50 ml/min)
- Give 10 mg/kg IV infused over 1 hour once daily for 7 to 14 days in Skin Infections (up to 21 days in Pneumonia)
-
Renal Dosing (eGFR<50 ml/min)
- Telavancin is NOT recommended when eGFR<50 ml/min (see adverse effects and contraindications)
- eGFR 30 to 50 ml/min: 7.5 mg/kg IV every 24 hours
- eGFR 10 to 29 ml/min: 10 mg/kg IV every 48 hours
VI. Adverse Effects
- See Glycopeptide Antibiotic
- QT Prolongation
- Nephrotoxic
- Monitor Renal Function every 2 to 3 days
- Avoid in eGFR <50 ml/min
- Accumulation of cyclodextrin carrier in renal dysfunction
VII. Safety
VIII. Drug Interactions
- Drug-Induced QTc Prolongation
- Falsely elevates coagulation studies (e.g. PTT, INR, Activated Clotting Time) for up to 18 hours after last dose
IX. Resources
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Lacy (2000) Drug Information Handbook, Lexi-Comp
- (2014) Presc Lett 21(8): 43
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Amino Acid, Peptide, or Protein (T116) , Antibiotic (T195) , Carbohydrate (T118) |
MSH | C487637 |
SnomedCT | 443552009, 443553004 |
LNC | LP158089-5, MTHU045743 |
English | TELAVANCIN, Telavancin, Telavancin (product), Telavancin (substance), Vancomycin, N(Sup 3'')-(2-(Decylamino)Ethyl)-29-(((Phosphonomethyl)Amino)Methyl)-, telavancin, (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-{[2-(decylamino)ethyl]amino}-5-hydroxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}-2 |
Spanish | telavancina, telavancina (sustancia), telavancina (producto) |